Table: Sumitomo Pharma -2024/25 group results (IFRS)

Sumitomo Pharma

13/05/2025 05:00

May 13 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 Year ended       Year ended       Year to        NEXT  
              Mar 31, 2025     Mar 31, 2024   Mar 31, 2026      YEAR    
                 LATEST          YEAR-AGO        COMPANY      COMPANY   
                 RESULTS          RESULT        FORECAST    H1 FORECAST 
  Sales          398.83           314.56         355.00                 
               (+26.8 pct)     (-43.4 pct)     (-11.0 pct)              
  Operating       28.80        loss 354.86        54.00                 
                                               (+87.5 pct)              
  Pretax
  Net             23.63        loss 314.97        40.00                 
                                               (+69.2 pct)              
  EPS Basic     59.49 yen    loss 792.79 yen   100.68 yen               
  Ann Div          NIL             NIL             NIL                  
  -Q2 Div          NIL             NIL             NIL                  
  -Q4 Div          NIL             NIL             NIL                  
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T